Gencitabine and carboplatin as first-line therapy in advanced/metastatic NSCLC

被引：0
|
作者：
Savio, G. [1 ]
Laudani, A. [1 ]
Usset, A. [1 ]
Leonardi, V. [1 ]
Pepe, A. [1 ]
Palmisano, V. [1 ]
Agostara, B. [1 ]
机构：
[1] Hosp M Ascoli ARNAS CIVICO, Dept Oncol, Palermo, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 25
页数：2
相关论文
共 50 条
  • [1] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [2] Carboplatin plus paclitaxel as first-line therapy for locally advanced recurrent metastatic endometrial cancer
    Attarian, H.
    Rezvani, H.
    Ghadyani, M.
    Okhovatian, A.
    Khosravi, A.
    Attarian, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A first for first-line therapy in NSCLC
    Rebecca Kirk
    [J]. Nature Reviews Clinical Oncology, 2011, 8 (12) : 691 - 691
  • [4] FIRST-LINE MEDICAL THERAPY IN ADVANCED METASTATIC RCC
    Porta, Camillo
    Giglione, Palma
    Lombardo, Fiorella
    Paglino, Chiara
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 6117 - 6118
  • [5] Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
    Dhillon, Sohita
    Syed, Yahiya Y.
    [J]. TARGETED ONCOLOGY, 2019, 14 (06) : 759 - 768
  • [6] Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
    Sohita Dhillon
    Yahiya Y. Syed
    [J]. Targeted Oncology, 2019, 14 : 759 - 768
  • [7] Phase I trial of Pemetrexed, Carboplatin and Sorafenib as first-line treatment in patients with metastatic NSCLC
    Brandts, C.
    Borchard, B.
    Waller, C. F.
    Martens, U. M.
    Kerhoff, A.
    Mohr, M.
    Young, C.
    Gerss, J.
    Serve, H.
    Berdel, W. E.
    Wiewrodt, R.
    [J]. ONKOLOGIE, 2010, 33 : 170 - 171
  • [8] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    [J]. ONKOLOGE, 2012, 18 (01): : 70 - 71
  • [9] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    [J]. ONKOLOGE, 2011, 17 (07): : 638 - 639
  • [10] Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
    Scott L.J.
    [J]. Drugs & Therapy Perspectives, 2018, 34 (8) : 351 - 357
12345